RE:RE:RE:Off Label Indications - Ethan Thomas post reminder I agree with your assessment, barcode. I would add a couple of things. First, I am very excited to see the latest Alstrom data. If as good as the earlier results, I can see PLI going thru the EAMS process to get early use (compassionate) and accelerated marketing approval in the UK. Secondly, the AS data along with the IPF data and that from other trials will better position PLI to strike partnership deals on 4050. Over the next 6 months or so PL needs to conclude at least one 4050 deal. I also hope to see partnership deals in the area of plasma proteins in coming months.